Bleeding Disorders Associated with Cancer

Area of Science:

• Hematology
• Oncology
• Coagulation Science

Background:

• Cancer is frequently associated with diverse coagulation defects, increasing the risk of bleeding complications.
• Specific hematologic disorders, such as primary hyperfibrinolytic syndrome in acute promyelocytic leukemia, represent severe bleeding risks.
• Malignancies can trigger rare conditions like acquired hemophilia, necessitating urgent diagnosis to avert catastrophic hemorrhage.

Purpose of the Study:

• To provide a comprehensive overview of coagulation defects linked to cancer.
• To highlight the clinical significance of recognizing and managing these bleeding risks.
• To emphasize the role of understanding hemostatic alterations in cancer patient care.

Main Methods:

• Review of established literature on cancer-associated coagulopathies.
• Analysis of clinical presentations and diagnostic challenges.
• Discussion of therapeutic implications and risk mitigation strategies.

Main Results:

• Several distinct coagulation defects are linked to cancer, ranging in severity.
• Acute promyelocytic leukemia-associated hyperfibrinolysis is a recognized severe bleeding disorder.
• Acquired hemophilia and acquired von Willebrand disease are other significant coagulopathies associated with malignancy.
• Anti-neoplastic drugs can also adversely affect hemostasis, elevating bleeding risk.

Conclusions:

• A thorough understanding of cancer-related coagulation disorders is essential for effective patient management.
• Early identification and intervention are critical for mitigating bleeding complications in cancer patients.
• Multidisciplinary approaches involving hematologists and oncologists can optimize outcomes.